Beta-Cell Function
Beta-cell function refers to the capacity of pancreatic beta-cells to secrete insulin in response to glucose. In Type 2 diabetes, beta-cell function declines progressively over years — the Defronzo “Ominous Octet” framework identifies beta-cell failure as the central driver of progression from controlled to insulin-dependent disease. Tirzepatide’s dual GIP and GLP-1 receptor agonism stimulates beta-cell insulin secretion in a glucose-dependent manner, meaning insulin release occurs when glucose is elevated but not during euglycaemia — the mechanism that confers the low hypoglycaemia risk seen in the SURPASS trials.
Surrogate marker evidence (PMID 38252888, J Clin Endocrinol Metab 2024): A post-hoc analysis of SURPASS-2 (tirzepatide vs semaglutide 1mg, both on metformin, n=1879) specifically assessed beta-cell function markers. Tirzepatide at all doses produced significantly greater improvements in HOMA2-IR (insulin resistance reduction: 15.5–24.0% vs 5.1% for semaglutide) and improvements in HOMA2-B (beta-cell secretory capacity). Critically, these improvements were consistent regardless of baseline beta-cell function quartile — meaning both patients with early T2D and those with substantially depleted beta-cell reserve showed improvement. Fasting C-peptide was reduced (consistent with improved insulin sensitivity rather than hypersecretion). The authors concluded tirzepatide “consistently improved markers of beta-cell function and insulin sensitivity” vs semaglutide.
Ontology Beta-Cell Function [relates] GIP Receptor Agonism Beta-Cell Function [relates] GLP-1 Receptor Agonism Beta-Cell Function [part-of] Type 2 Diabetes Beta-Cell Function [evidence_from] SURPASS-2
HbA1c normalisation / diabetes remission (PMC 12409195, post-hoc SURPASS trials): Across the SURPASS programme (primarily SURPASS-1, -2, -3), 13–62% of T2D patients achieved HbA1c <5.7% (the threshold for “normal glucose tolerance” rather than T2D) at 52 weeks, depending on dose and baseline HbA1c. In SURPASS-1 monotherapy (no background OAD), mean HbA1c reached 5.9–6.1% at 40 weeks on tirzepatide 10–15mg — near-normal range, previously unseen with any T2D pharmacotherapy. These figures are considerably higher than semaglutide or dulaglutide monotherapy benchmarks. Weight loss mediates approximately 50% of the glycaemic improvement; the remainder appears to be a weight-independent GIP/GLP-1 mechanism. This does not imply structural beta-cell recovery — it reflects pharmacological glucose normalisation.
Ontology Beta-Cell Function [evidence_from] SURPASS-1 Beta-Cell Function [relates] Weight Loss in T2D Beta-Cell Function [relates] Stopping Effects and Treatment Dependence
The “remission” question — important caveat: The concept of “diabetes remission” (defined as HbA1c <6.5% for ≥3 months off pharmacotherapy) requires treatment discontinuation. SURMOUNT-4 withdrawal data (and the general GLP-1 RA pharmacology literature) shows that glycaemic gains reverse substantially within months of stopping tirzepatide. This means the near-normal HbA1c achieved during treatment represents pharmacological control of a chronic disease, not disease modification or beta-cell recovery. The appropriate framing is “sustained glycaemic normalisation while on treatment” — valuable for patients, but distinct from structural remission as achieved with bariatric surgery. Whether continuous-use tirzepatide delays the natural history of beta-cell failure (by reducing glucotoxicity over years) is an important unanswered question not yet addressed in trial data.
Ontology Beta-Cell Function [relates] Stopping Effects and Treatment Dependence Beta-Cell Function [contradicts] Advanced T2D High-Dose Insulin
Numbers
| Measure | Finding | Source |
|---|---|---|
| HOMA2-IR reduction (tirzepatide 5/10/15mg) | 15.5/20.8/24.0% | SURPASS-2 post-hoc (PMID 38252888) |
| HOMA2-IR reduction (semaglutide 1mg) | 5.1% | SURPASS-2 post-hoc |
| HbA1c <5.7% achievement — SURPASS range | 13–62% | PMC 12409195 post-hoc |
| Mean HbA1c (SURPASS-1 monotherapy, 15mg) | 5.9–6.1% | SURPASS-1 |
| Weight loss contribution to HbA1c improvement | ~50% | Mediation analysis |
Practical Interpretation
- Who this matters for: T2D patients with residual beta-cell function (typically <10 years disease duration, BMI ≥27, not fully insulin-dependent)
- Framing for patients: “Tirzepatide can bring blood sugar back to normal range in many people — but this requires continuing the medication”
- Distinction from remission: Treatment discontinuation reverses glycaemic benefit; this is NOT structural beta-cell recovery
- Unanswered: Whether long-term tirzepatide use (by reducing glucotoxicity) slows progressive beta-cell failure
Connections
- Tirzepatide — relates (glucose-dependent mechanism)
- GIP Receptor Agonism — mediates (insulin secretion stimulation)
- GLP-1 Receptor Agonism — mediates (insulin secretion stimulation)
- SURPASS-2 — evidence_from (HOMA2 post-hoc data)
- SURPASS-1 — evidence_from (monotherapy near-normal HbA1c)
- Stopping Effects and Treatment Dependence — relates (reversal on discontinuation)
- Advanced T2D High-Dose Insulin — contrasts (beta-cell function context)